1. Home
  2. ALT vs ANTA Comparison

ALT vs ANTA Comparison

Compare ALT & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ANTA
  • Stock Information
  • Founded
  • ALT 1997
  • ANTA 2022
  • Country
  • ALT United States
  • ANTA Singapore
  • Employees
  • ALT N/A
  • ANTA N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ANTA Investment Bankers/Brokers/Service
  • Sector
  • ALT Health Care
  • ANTA Finance
  • Exchange
  • ALT Nasdaq
  • ANTA Nasdaq
  • Market Cap
  • ALT 327.4M
  • ANTA 294.7M
  • IPO Year
  • ALT N/A
  • ANTA 2025
  • Fundamental
  • Price
  • ALT $3.87
  • ANTA $11.80
  • Analyst Decision
  • ALT Strong Buy
  • ANTA Strong Buy
  • Analyst Count
  • ALT 6
  • ANTA 2
  • Target Price
  • ALT $17.40
  • ANTA $19.25
  • AVG Volume (30 Days)
  • ALT 2.5M
  • ANTA 18.1K
  • Earning Date
  • ALT 11-11-2025
  • ANTA 08-12-2025
  • Dividend Yield
  • ALT N/A
  • ANTA N/A
  • EPS Growth
  • ALT N/A
  • ANTA N/A
  • EPS
  • ALT N/A
  • ANTA 0.24
  • Revenue
  • ALT $20,000.00
  • ANTA $56,997,910.00
  • Revenue This Year
  • ALT N/A
  • ANTA $65.94
  • Revenue Next Year
  • ALT $761,880.20
  • ANTA $59.39
  • P/E Ratio
  • ALT N/A
  • ANTA $48.84
  • Revenue Growth
  • ALT N/A
  • ANTA 405.62
  • 52 Week Low
  • ALT $2.90
  • ANTA $10.19
  • 52 Week High
  • ALT $11.16
  • ANTA $27.72
  • Technical
  • Relative Strength Index (RSI)
  • ALT 55.49
  • ANTA N/A
  • Support Level
  • ALT $3.56
  • ANTA N/A
  • Resistance Level
  • ALT $3.72
  • ANTA N/A
  • Average True Range (ATR)
  • ALT 0.18
  • ANTA 0.00
  • MACD
  • ALT 0.03
  • ANTA 0.00
  • Stochastic Oscillator
  • ALT 51.15
  • ANTA 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ANTA Antalpha Platform Holding Company Ordinary Shares

Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.

Share on Social Networks: